Search clinical trials for: Intermediate or high risk myelodysplastic syndrome

Total 235600 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic... and other conditions

United States
St. Antonius Hospital
UMC Utrecht; Leiden University Medical Center; Medical Centre Leeuwarden; Rijnstate... and other collaborators

Completed

Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly (POPular AGE)

Unstable Angina | Non-ST-elevation Acute Coronary Syndrome | Non-ST-elevation Myocardial Infarction

Netherlands
National Cancer Institute (NCI)

Completed

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Familial Ovarian Cancer | Familial Breast Cancer | BRCA1-associate Malignancies | BRCA2-associated Malignancies

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Neoplasms | Myelodysplastic Syndromes | Non-Hodgkin Lymphoma | Solid Tumor, Adult

United States, Spain, Israel, Germany, Canada
University of Chicago

Active, not recruiting

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Prostate Cancer

United States
Pfizer

Terminated

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

COVID-19

United States
Memorial Sloan Kettering Cancer Center

Completed

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Myelodysplastic Syndromes (MDS) | Acute Myelogenous Leukemia (AML)

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditions

United States
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Myelodysplastic Syndromes

Israel, United States, Korea, Republic of, Australia, France, Germany, Spain, United Kingdom, Czechia, Austria, Italy, Greece, Poland
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Prostate Cancer

United States
Mahidol University
National Institute of Mental Health (NIMH); University of Malaya; University...

Active, not recruiting

Addressing the Continuum of Care Among High-risk Thai Men

HIV/AIDS | STD

Thailand
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

High Risk Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia

United States
University of Birmingham
AstraZeneca; Cancer Trials Ireland

Active, not recruiting

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) (CompARE)

Oropharyngeal Cancer

United Kingdom, Ireland
Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Myelodysplastic Syndromes

Spain, United States, Belgium, Canada, Germany, Italy
University of California, San Francisco
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition

HIV Infections | Bacterial Vaginosis

South Africa
Amgen

Completed

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Higher Risk Myelodysplastic Syndrome

United States
Indiana University

Withdrawn

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia, Adult | Bone Marrow Transplant Complications

United States
Medical College of Wisconsin

Active, not recruiting

Increasing PrEP Use in High-Risk Social Networks of African-American MSM in Underserved Low-Risk Cities (SNAP)

Human Immunodeficiency Virus

United States
Shanghai Antengene Corporation Limited

Terminated

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) (HATCH)

Myelodysplastic Syndrome

China
Hunter College of City University of New York
National Institute on Drug Abuse (NIDA); University of Michigan

Enrolling by invitation

Evaluating the Efficacy of Annual CHTC Retesting Among Male Couples at High Risk of HIV Infection (4Us Part B)

HIV Infections

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI); University of Florida; The Pew Charitable Trusts

Active, not recruiting

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Brain and Central Nervous System Tumors

United States, Australia
Washington University School of Medicine
Jazz Pharmaceuticals

Active, not recruiting

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer

BRCA1 Syndrome | BRCA2 Syndrome | No Evidence of Disease | Hereditary Ovarian Carcinoma | Hereditary Female Breast Carcinoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia, Switzerland
Fred Hutchinson Cancer Center
HighPass Bio, Inc.

Suspended

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Loss of Chromosome 17p

United States
The University of Texas Health Science Center,...
Vyaire Medical

Completed

Effect of Nasal Positive Airway Pressure Versus Standard Care on Oxygenation and Ventilation During Propofol-based Sedation for Colonoscopy in Patients With High Risk of Airway Obstruction

Obstructive Sleep Apnea, Obesity

United States
Edwards Lifesciences

Completed

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk (PII A)

Symptomatic Severe Aortic Stenosis

United States, Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...
MacroGenics

Active, not recruiting

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

Fatigue | Overweight | Lynch Syndrome | Chronic Lymphocytic Leukemia | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Breast Carcinoma | Cancer Survivor | Ovarian Carcinoma | Health Status Unknown | Body Mass Index 25 or Greater

United States
MorphoSys AG

Active, not recruiting

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND)

Diffuse Large B-cell Lymphoma

Germany, France, Hungary, Italy, Spain, United States, Austria, Czechia, Australia, Israel, Korea, Republic of, Turkey, Taiwan, Argentina, Canada, Colombia, Ireland, Japan, Malaysia, New Zealand, Philippines, Poland, Romania, Russian... and more
Memorial Sloan Kettering Cancer Center
Ferring Pharmaceuticals

Active, not recruiting

Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

Prostate Cancer | Prostatic Adenocarcinoma

United States
Hospices Civils de Lyon

Active, not recruiting

Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer (FOCALE)

Prostate Cancer

France, Sweden
CSSS de Gatineau

Active, not recruiting

Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer

Prostate Cancer

Canada
ExCellThera inc.
Fred Hutchinson Cancer Center

Active, not recruiting

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

High Risk Hematological Malignancy | Cord Blood Transplant

United States, Netherlands
Ciusss de L'Est de l'Île de Montréal
ExCellThera inc.; Stem Cell Network

Active, not recruiting

UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia

Cord Blood Transplant | High Risk Hematologic Malignancy

Canada
Ashok Muthukrishnan
Progenics Pharmaceuticals, Inc.

Terminated

18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer

Prostate Cancer

United States
Hemavant Sciences GmbH

Terminated

A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes (Encore-MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

Korea, Republic of, United States, Taiwan, Belgium, France, Spain, Italy
Weill Medical College of Cornell University
New York Blood Center

Terminated

IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Unity Health Toronto
University of Manitoba; University of British Columbia; Canadian Institutes of... and other collaborators

Completed

The Combined Portfolio Diet and Exercise Study (PortfolioEx)

Cardiovascular Diseases | Metabolic Syndrome | Type 2 Diabetes | Hypercholesterolemia

Canada
Uwe Platzbecker
Gilead Sciences

Withdrawn

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS (MAGROLIC)

Acute Myeloid Leukemia | Myelodysplastic Neoplasm
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
Syros Pharmaceuticals

Completed

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, France
Prof. Dr. Jörg Leuppi

Terminated

Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS

Covid19 | Corona Virus Infection | ARDS | Aviptadil

Switzerland
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Myeloproliferative... and other conditions

United States
Silence Therapeutics plc

Completed

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Non-transfusion-dependent Thalassemia | Low Risk Myelodysplastic Syndrome | Very-Low Risk Myelodysplastic Syndrome

Thailand, Israel, Jordan, United Kingdom, Germany, Italy, Malaysia
Andrei Iagaru

Completed

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States
Fudan University

Active, not recruiting

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Neoadjuvant Therapy | High-risk Prostate Cancer

China

Search clinical trials for: Intermediate or high risk myelodysplastic syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations